temozolomide has been researched along with ceritinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alshareef, M; Cachia, D; Das, A; Infinger, LK; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK | 1 |
| Honda-Kitahara, M; Ichimura, K; Iwadate, Y; Kawauchi, D; Kobayashi, T; Narita, Y; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Yamamuro, S | 1 |
2 other study(ies) available for temozolomide and ceritinib
| Article | Year |
|---|---|
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Pharmaceutical Preparations; Phosphatidylinositol 3-Kinases; Pyrimidines; Sulfones; Temozolomide; Triazines; Tumor Suppressor Proteins | 2020 |
The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Brain Neoplasms; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfones; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |